Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Exclusion Criteria

• •1. Subjects who used any of the following systemic treatments during the washout periods given below:
• •1. Oral corticosteroid dose of prednisone \>7.5 mg/day (or equivalent) or a change in dose within 28 days of baseline.
• •2. Treatment with more than 1 NSAID within 14 days at baseline.
• •3. Methotrexate dose greater than 25 mg/week, or change in the dose of methotrexate within 28 days of baseline.
• •4. Subjects will be allowed to continue the following non biologic DMARDs: sulfasalazine, hydroxychloroquine, and leflumomide. All other non-biologic DMARDs (including but not limited to gold, penicillamine, azathioprine, cyclophospamide), and biologic DMARDs must have been discontinued at least 2 months prior to Week 1.
• •5. Any biologic B cell depleting agent (eg, rituximab) within 2 years of Week 1.
• •2. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.
• •3. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.